Better Health for All

Relay Therapeutics is a clinical-stage precision medicine company whose entire business is devoted to developing life-changing therapies for debilitating and life-threatening diseases, including precision oncology and genetic diseases.

All 8 of its programs are aimed at treating serious conditions, with no revenue from products with negative health impacts. However, its investigational product RLY-2608, in combination with fulvestrant, showed that 36% of patients experienced a Grade 3 treatment-related adverse event (TRAE), and 3% experienced Grade 3 hyperglycemia. The company does not currently make investigational products available through expanded access programs. Relay Therapeutics targets specific patient populations for its programs, such as an estimated 170,000 people in the U.S. with PI3Kα mutation-driven vascular malformations, 8,000 with Fabry disease, and 28,000 diagnosed annually with mutated NRAS solid tumors. The company's 10-K filing includes an extensive 'Risk Factors' section and a 'Special Note Regarding Forward-Looking Statements'. Relay Therapeutics has made cash payments to D. E. Shaw Research totaling $54.3 million through December 31, 2024, for its Dynamo platform, which has produced eight drug candidates and four Investigational New Drug Applications since 2016. The company reported $73.8 million in R&D expenses in Q1 2025 and $319.1 million for the full year 2024. The company's hazardous waste and lab waste intensity was 188 lbs per employee in 2020, with 40% recycled. In 2020, the company supported BAGLY through a company-wide fundraising event and conducted a gender pay gap analysis showing no discrepancy. As of December 31, 2024, 49% of employees were female and 31% of employees and 25% of leadership identified as being from diverse racial and ethnic groups. The company had 261 full-time employees as of December 31, 2024, with 80% engaged in R&D. In response to COVID-19, the company implemented safety protocols and provided onsite testing. The company follows GDPR, UK GDPR, and the UK Data Protection Act 2018 for personal data collection and use. Clinical trials follow ICH/GCP principles, require IRB approval, and involve informed consent processes.

Fair Pay & Worker Respect

The CEO to median employee pay ratio for 2024 was 44:1, with the CEO receiving $13,079,301 and the median employee receiving $298,080.

The company announced layoffs of approximately 10% of its workforce (about 30 employees) in October 2024, following earlier layoffs of less than 5% in July 2024 when the company employed about 300 people. In April 2025, an additional 70 employees were laid off. Relay Therapeutics adopted an EHS Policy and a Human Rights Policy on April 1, 2022, committing to providing a safe workplace, tracking incident rates, ensuring equal employment opportunities, and complying with laws prohibiting child, forced, or indentured labor. The company's Code of Business Conduct and Ethics, adopted June 23, 2020, includes a whistleblower hotline and an online reporting option, and forbids retaliation against employees who report suspected misconduct in good faith.

Kind to Animals

Relay Therapeutics conducts animal studies to assess drug activity and tolerability in vivo, which are a required part of preclinical testing.

These studies adhere to guidelines approved by Institutional Animal Care and Use Committees and the Association for Assessment and Accreditation of Laboratory Animal Care. The company also employs non-animal methods such as molecular dynamics simulations, cryo-electron microscopy, and in vitro testing as part of its preclinical studies.

Respect for Cultures & Communities

The company has 3 formal partnerships with local community groups, including Cradles to Crayons, BAGLY (The Boston Alliance of Gay, Lesbian, Bisexual and Transgender Youth), and Harvard Medical School Office for Diversity Inclusion and Community Partnership.

No cultural appropriation incidents have been reported. Free, Prior, and Informed Consent (FPIC) processes are not applicable to the company's operations, as there is no mention of engagement with indigenous peoples. The company does not operate near cultural or heritage sites, so no disruptions have occurred.